重大事件
即時報告
8-K
2026-06-02
Kyverna Therapeutics提交8-K披露股东投票結果
AI 繁中摘要
Kyverna Therapeutics（納斯達克：KYTX）於2026年6月2日提交8-K申報，報告期為2026年5月27日，主要根據Item 5.07披露股東投票結果，並附Item 9.01財務報表及附件。該公司為總部位於加州愛莫利維爾的臨床階段生物製藥企業，專注生物製品領域。是次8-K未提供具體投票明細，實際結果需參閱內嵌XBRL及附加展品。投資者應關注相關決議對公司治理及未來資本規劃的潛在影響。🔍📄
展開英文正文
EDGAR Filing Documents for 0001193125-26-253604 SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001193125-26-253604 Filing Date 2026-06-02 Accepted 2026-06-02 16:30:16 Documents 9 Period of Report 2026-05-27 Items Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K kytx-20260527.htm iXBRL 8-K 66209 Complete submission text file 0001193125-26-253604.txt 172858 Data Files Seq Description Document Type Size 2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kytx-20260527.xsd EX-101.SCH 24834 12 EXTRACTED XBRL INSTANCE DOCUMENT kytx-20260527_htm.xml XML 4717 Mailing Address 5980 HORTON STREET SUITE 200 EMERYVILLE CA Business Address 5980 HORTON STREET SUITE 200 EMERYVILLE CA 5109252492 Kyverna Therapeutics, Inc. (Filer) CIK: 0001994702 (see all company filings) EIN.: 831365441 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-41947 | Film No.: 261056541 SIC: 2836 Biological Products, (No Diagnostic Substances) (CF Office: 03 Life Sciences)